EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

The combined effect of systemic antibiotics and proton pump inhibitors on Clostridioides difficile infection and recurrence

Nele Moreels, Annelies Boven, Oswaldo Gressani, Fredrik L Andersson, Erika Vlieghe, Steven Callens, Lars Engstrand, Johanna Simin, Nele Brusselaers iD

Journal of Antimicrobial Chemotherapy · 01.03.2024 · 79 (3) · 608-616

DOI: 10.1093/jac/dkae012 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Antimicrobial Chemotherapy, online erschienen am 24.01.2024. Verfasst von Nele Moreels und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Microbiology, Centre for Translational Microbiome Research, Tumour and Cell Biology, Karolinska Institutet, Stockholm, Sweden. Hauptthemen laut MEDLINE: Clostridium Infections, Quinolones. Die Arbeit wurde bisher 26-mal zitiert (Crossref) und nennt 69 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Centre for Translational Microbiome Research, Karolinska Instituted, Sweden, Research Collaboration Agreement with Ferring Pharmaceuticals.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Antibiotics and proton pump inhibitors (PPI) are recognized risk factors for acquisition and recurrence of Clostridioides difficile infection (CDI), yet combined effects remain unclear.

Objectives

To assess the short- and long-term effects of antibiotics and PPIs on CDI risk and recurrence.

Methods

Population-based study including all 43 152 patients diagnosed with CDI in Sweden (2006–2019), and 355 172 matched population controls without CDI. The impact of antibiotics and PPIs on CDI risk and recurrence was explored for recent (0–30 days) and preceding (31–180 days) use prior to their first CDI diagnosis, using multivariable conditional logistic regression presented as odds ratios (ORs) and 95% confidence interval, adjusted for demographics, comorbidities and other drugs.

Results

Compared to controls, the combined effect of recent PPIs and antibiotics [ORAB+PPI = 17.51 (17.48–17.53)] on CDI risk was stronger than the individual effects [ORAB = 15.37 (14.83–15.93); ORPPI = 2.65 (2.54–2.76)]. Results were less pronounced for exposure during the preceding months. Dose–response analyses showed increasing exposure correlated with CDI risk [recent use: ORAB = 6.32 (6.15–6.49); ORPPI = 1.65 (1.62–1.68) per prescription increase]. Compared to individuals without recurrence (rCDI), recent [ORAB = 1.30 (1.23–1.38)] and preceding [ORAB = 1.23 (1.16–1.31); ORPPI = 1.12 (1.03–1.21)] use also affected the risk of recurrence yet without significant interaction between both. Recent macrolides/lincosamides/streptogramins; other antibacterials including nitroimidazole derivates; non-penicillin beta lactams and quinolones showed the strongest association with CDI risk and recurrence, particularly for recent use. PPI use, both recent and preceding, further increased the CDI risk associated with almost all antibiotic classes.

Conclusion

Recent and less recent use of PPIs and systemic antibiotics was associated with an increased risk of CDI, particularly in combination.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Clostridium InfectionsQuinolonesHumansAnti-Bacterial AgentsProton Pump InhibitorsStreptogramins

Substanzen

Anti-Bacterial AgentsProton Pump InhibitorsStreptograminsQuinolones

Autor:innen und Institutionen

  • Department of Microbiology, Centre for Translational Microbiome Research, Tumour and Cell Biology, Karolinska Institutet, Stockholm, Sweden.
  • I-BioStat, Data Science Institute, Hasselt University, Hasselt, Belgium.
  • Department of Family Medicine and Population Health, Global Health Institute, Antwerp University, Antwerp, Belgium.
  • Global Value & Access, Ferring Pharmaceuticals, Copenhagen, Denmark.
  • Department of Internal Medicine and Pediatrics, General Internal Medicine, Ghent University, Ghent, Belgium.
  • Department of Public Health and Primary Care, Ghent University, Ghent, Belgium.

ORCID-Profile: Nele Brusselaers

Förderung

  • Centre for Translational Microbiome Research
  • Karolinska Instituted, Sweden
  • Research Collaboration Agreement with Ferring Pharmaceuticals

Zitieren

APA

Moreels, N., Boven, A., Gressani, O., Andersson, F. L., Vlieghe, E., Callens, S., Engstrand, L., Simin, J., & Brusselaers, N. (2024). The combined effect of systemic antibiotics and proton pump inhibitors on Clostridioides difficile infection and recurrence. Journal of Antimicrobial Chemotherapy, 79(3), 608-616. https://doi.org/10.1093/jac/dkae012

Vancouver

Moreels N, Boven A, Gressani O, Andersson FL, Vlieghe E, Callens S, et al. The combined effect of systemic antibiotics and proton pump inhibitors on Clostridioides difficile infection and recurrence. Journal of Antimicrobial Chemotherapy. 2024;79(3):608-616. doi:10.1093/jac/dkae012

BibTeX
@article{Moreels2024,
  author = {Moreels, Nele and Boven, Annelies and Gressani, Oswaldo and Andersson, Fredrik L and Vlieghe, Erika and Callens, Steven and Engstrand, Lars and Simin, Johanna and Brusselaers, Nele},
  title = {The combined effect of systemic antibiotics and proton pump inhibitors on Clostridioides difficile infection and recurrence},
  journal = {Journal of Antimicrobial Chemotherapy},
  year = {2024},
  volume = {79},
  number = {3},
  pages = {608--616},
  doi = {10.1093/jac/dkae012}
}
Kostenlos starten →